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Abstract The aim of this study was to compare the
expressions of mRNA for metalloproteinases (MMP-2 and
MMP-9) and type IV collagen in two different histological
types of basal-cell carcinoma (BCCs; nodular and infiltra-
tive) and in normal tissues from the tumor interface. The
study included biopsy specimens of the skin involved with
BCC and normal skin adjacent the lesion. The expressions
of mRNA for MMP-2, MMP-9 and type IV collagen were
determined by means of RT-PCR (Reverse transcription
polymerase chain reaction). The level of type IV collagen
mRNA in nodular and infiltrative BCCs turned out to be
significantly lower, and the expressions of MMP-2 and
MMP-9 mRNA significantly higher than in normal tissues
adjacent to these tumors. The expression of mRNA for
MMP-9 but not for MMP-2 was significantly higher in
infiltrative BCCs than in the nodular BCCs. In turn, normal
tissues adjacent to nodular BCCs showed significantly
higher levels of mRNA for MMP-2 and significantly lower
levels of type IV collagen mRNA than the normal tissues
from the interface of infiltrative BCCs. The findings sug-
gest that MMP-2 and MMP-9 could be used as prognostic
factors of BCCs.
Keywords Basal-cell carcinoma  Matrix
metalloproteinases  Type IV collagen  Molecular
diagnosis  Invasiveness  Resection margin
Introduction
Cancers constitute a significant problem of modern medi-
cine [1], being the second leading cause of mortality
worldwide [2, 3]. Despite extensive research, the path-
omechanism of carcinogenesis is still not completely
understood. Non-melanoma skin cancers (NMSCs) are the
most frequent human malignancies, characterized by con-
stantly increasing incidence [4–6]. Basal-cell carcinoma
(BCC), especially its nodular and infiltrative forms, rep-
resent a considerable fraction of all NMSCs (75–80 %)
[7–9]. A dramatic increase in the incidence of BCC has
been recently observed in Europe, United States and Aus-
tralia, especially among Caucasians [10, 11]. Although
BCC is typically diagnosed at older age, mean age at
diagnosis still decreases, and this malignancy can be spo-
radically found in teenagers [6].
BCC is characterized by a slow infiltrative growth
resulting in destruction of surrounding structures. Most
BCCs are not invasive, rarely form metastases or lead to
mortality [9, 12]. However, delayed diagnosis and resultant
local progression of the tumor may lead to involvement of
surrounding tissues [13, 14] and serious anatomical
deformations, especially in the case of face [4, 15]. This
may exert significant detrimental effect on the quality of
life of BCC patients [16, 17].
Metalloproteinases 2 and 9 (MMP-2 and MMP-9),
enzymes from the gelatinase family, and their inhibitors
play important role in the progression of BCC [18–20].
Due to degradation of type IV collagen by MMP, cancer
cells can migrate outside the tumor and form distant
metastases [21]. A key role in this process is ascribed to
MMP-9, which acts as a promotor of tumor invasion
[22, 23]. An increase in the expression of MMP-9 was
shown to correlate with clinical stage of BCC and more
& Anna Goździalska
anna.gozdzialska@gmail.com
1 Department of Health and Medical Sciences, Andrzej Frycz
Modrzewski Krakow University, 1 G. Herlinga-
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aggressive phenotype of this cancer [21, 24, 25]. Further-
more, MMP-9 plays an important role in the process of
neoangiogenesis, being involved in the proliferation of
endothelial cells and activation of pro-angiogenic factors
[20, 24–27].
Correct diagnosis constitutes a crucial component of
BCC management. Diagnosed at early stages, this cancer is
fully curable. Most BCCs of the skin can be readily diag-
nosed on physical examination [6, 28]. Macroscopic eval-
uation of the tumor is usually sufficient for establishing
correct diagnosis, and histopathological analysis allows to
identify the type of tumor growth [9]. Furthermore,
microscopic examination of the biopsy specimen is crucial
for therapeutic decisions, namely selection of optimal
technique for surgical resection. Unfortunately, the resec-
tions of BCC are suboptimal in many cases which is
reflected by high rates of local recurrences [29]. This
typically results from the problems with correct identifi-
cation of resection margin.
Progress in molecular biology has revolutionized
approach to diagnosis and treatment of cancers [30, 31].
Molecular examination of the biopsy specimens can be
helpful in determining the stage of tumor and appropriate
identification of resection margins. Consequently, we
decided to verify if molecular techniques can be helpful in
the diagnosis and management of BCC. Therefore, the aim
of this study was to compare the expressions of mRNA for
metalloproteinases (MMP-2 and MMP-9) and type IV
collagen in two different histological types of BCC
(nodular and infiltrative) and in normal tissues from the
tumor interface.
Materials and methods
Patients
The protocol of the study was approved by the Local
Bioethics Committee at the Jagiellonian University in
Krakow (decision no. KBET/37/B/2009).
The study included biopsy specimens of the skin involved
with BCC, as well as the biopsy specimens from normal skin
adjacent the lesion. The samples from the tumors and normal
skin were obtained from the same patients (n = 70, 28
women and 42 men), during surgical resections of BCCs,
performed at the Clinical Department of Dermatology,
University Hospital in Krakow. All of patients are Cau-
casian. 35 patients (14 women and 21 men) presented with
infiltrative BCCs, and another 35 (14 women and 21 men)
with nodular BCCs. Mean age of the patients was
68 ± 10.6 years for women and 67 ± 10.8 years for men
with infiltrative BCCs and 74 ± 6.7 years for women and
76 ± 6.5 years for men with nodular BCCs.
Methods
The biopsy specimens from BCCs and normal adjacent
skin were used to determine the expressions of mRNA for
MMP-2 (MMP-2), MMP-9 (MMP-9) and type IV collagen
(COL4A4) genes, as well as for beta-actin gene (ACTB),
used as a reporter gene. 30-mg samples were obtained from
each specimen, previously fixed in a RNAlater RNA Sta-
bilization Reagent (Qiagen, Germany), and pulverized in
liquid nitrogen. Total RNA was isolated at 4 C in a DNA/
RNA UV-Cleaner UVC/T-AR chamber (Biosan, Latvia),
using a modified method described by Chomczynski and
Sacchi [32]. Concentration and purity of the extracted RNA
were determined spectrophotometrically.
The samples for reverse transcription were prepared in
the DNA/RNA UV-Cleaner UVC/T-AR chamber (Biosan,
Latvia). The reaction was conducted with an aid of a
Revert Aid H Minus First Strand cDNA Synthesis Kit
(Fermentas, Lithuania). The resultant cDNA templates
were subjected to PCR with an Opti Taq hot start
polymerase (Eurx, Poland) and a set of specific primers
(MMP-2: F50-CACTTTCCTGGGCAACAAAT-30 and
R50-CTCCTCAATGCCCTTGATGT-30 at 10 lM; MMP-
9: F50-TCCCTGGAGACCTGAGAACC-30 and R50-GT
CGTCGGTGTCGTAGTTGG-30 at 10 lM; COL4A4:
F50-CCCCTCAGGACCAGGGTGCAA-30 and R50-AGG
GGCGGATCGCCTCTTCCA-30 at 4 lM; ACTB: F50-GG
ACTTCGAGCAAGAGATGG-30 and R50-AGCACTG
TGTTGGCGTACAG-30 at 6 lM). All the primers were
synthesized at DNA Gdansk (Poland). The resultant
amplicons of MMP-2 (271 kbp), MMP-9 (659 kbp),
COL4A4 (482 kbp) and ACTB (234 kbp) were separated
by electrophoresis in a 1.5 % agarose gel with ethidium
bromide, using a horizontal electrophoresis system
(Kucharczyk, Poland). The electrophoretograms were
photographed with an aid of a digital camera (Olympus,
USA), UV transilluminator (Vilber Lourmat, France) and
PolyDoc system for electrophoretic gel documentation and
analysis. The digital recordings of the electrophoretograms
were subjected to densitometric analysis with Quantity One
4.2.1 software (Bio-Rad, USA). The density of the RT PCR
products was considered as an equivalent of MMP-2,
MMP-9, type IV collagen and beta-actin mRNA
expressions.
Statistical analysis
Statistical analysis was conducted with a SPSS 18 package
(IBM, USA). Continuous variables were examined with
Kolmogorov–Smirnov test for normality of their distribu-
tions, and Student t test was used for intergroup compar-
isons. The results of the two tests were considered
significant at p B 0.05.
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Results
The level of type IV collagen mRNA in nodular BCCs
turned out to be significantly lower (by 31 %), and the
expressions of MMP-2 and MMP-9 mRNA significantly
higher (by 293 and 486 %, respectively) than in normal
tissues adjacent to these tumors (p\ 0.001 for all the
comparisons). Also in the case of infiltrative BCCs, the
expression of type IV collagen mRNA was shown to be
significantly lower (by 67 %) and the levels of MMP-2 and
MMP-9 mRNA significantly higher (by 427 and 883 %,
respectively) than in the adjacent normal tissues (p\ 0.001
for all the comparisons; Figs. 1, 2).
The expression of mRNA for MMP-9 (56 % difference,
p\ 0.001), but not for MMP-2 (11 % difference,
p = 0.097), turned out to be significantly higher in infil-
trative BCCs than in the nodular BCCs. The two tumor
types did not differ significantly in terms of their type IV
collagen mRNA expressions (p = 0.166). In turn, normal
tissues adjacent to nodular BCCs showed significantly
higher levels of mRNA for MMP-2 (32 % difference,
p = 0.001), but not MMP-9 (17 % difference, p = 0.209),
and significantly lower levels of type IV collagen mRNA
(17 % difference, p\ 0.001) than the normal tissues from
the interface of infiltrative BCCs (Figs. 1, 2).
In group of nodular BCC, between women and men, the
expression of mRNA for MMP-2, MMP-9 and type IV
collagen did not differ significantly (Table 1). In group of
infiltrative BCC, only expression of type IV collagen was
significantly higher in men as compared to women
(Table 2).
Discussion
We analyzed the expressions of mRNA transcripts for
MMP-2, MMP-9 and type IV collagen in nodular and
infiltrative BCCs. Quantitative analysis of mature mRNA
transcripts enabled us to appropriately asses the expression
of these proteins, as their biosynthesis is mostly regulated
at a transcriptional and post-transcriptional level. Exami-
nation of mature mRNA transcripts (possible due to
application of appropriate primers) is suitable for the
evaluation of gene expression after the post-transcriptional
modification.
Expression of mRNA for MMP-2, MMP-9 and type
IV collagen
We showed that the expressions of mRNA for MMP-2 and
MMP-9 in nodular and infiltrative BCCs were significantly
higher than in normal tissues adjacent to these tumors; this
observation supports existing evidence on the involvement
of metalloproteinases in carcinogenesis. MMP-2 and
MMP-9 catalyze proteolysis of type IV collagen, and thus
participate in the destruction of the basement membrane
barrier. Due to presence of specific catalytic domain,
MMP-2 and MMP-9 can degrade virtually all components
of this barrier. Cancer cells can release metalloproteinases
or stimulate synthesis thereof in normal tissues, e.g. via the
secretion of extracellular matrix metalloproteinase inducer
(EMMPRIM) [33, 34]. Moreover, metalloproteinases may
be synthesized by the transformed cells themselves [35].
Enhanced proteolysis of extracellular matrix (ECM) and
Fig. 1 Mean (±SD)
expressions of mRNA for type
IV collagen in the tissues (T) of
nodular (nBCC) and infiltrative
(iBCC) basal-cell carcinoma
and in normal tissues adjacent to
the tumors (NT)
Mol Biol Rep (2016) 43:1027–1033 1029
123
resultant degradation of type IV collagen, the main com-
ponent of the basement membrane, enable growth of a
tumor and migration of cancer cells to blood vessels, and
then to distant tissues and organs [6].
Carcinogenesis is associated with overexpression of the
metalloproteinase genes and increase in the enzymatic
activity of their products. The overexpression is associated
with regulation of genes at a transcriptional level, involv-
ing such transcription factors as AP-1 and AP-2. Cancer
tissues were demonstrated to express latent forms of met-
alloproteinases and show decreased expression of metal-
loproteinase inhibitors, such as tissue inhibitors of
metalloproteinases (TIMPs) and alpha-2-macroglobulin
[36].
Both metalloproteinases (MMP-2and MMP-9) and type
IV collagen are involved in angiogenesis, which is vital for
tumor growth and invasion [37, 38]. Enhanced expression
of mRNA for metalloproteinases leads to excessive
degradation of ECM [39]. Under physiological conditions,
the degradation of ECM is tightly controlled due to regu-
lation of expression and activity of proteolytic enzymes
[35]. However, this control mechanisms are disrupted
under pathological conditions, e.g. in the BCC tissues [9].
The abovementioned changes in the expressions of MMP-2
and MMP-9 lead to structural alterations of the basement
membrane and ECM [40]; as a result, endothelial cells can
freely migrate inside the tumor and form new blood vessels
necessary for its further growth [41, 42].
Nodular versus infiltrative BCCs
The expression of mRNA for MMP-2 in nodular BCCs
turned out to be lower than in the infiltrative BCCs. This
points to greater invasiveness of the infiltrative BCC; cat-
alyzing proteolysis of the basement membrane, metallo-
proteinases enable cancer cells to infiltrate to adjacent
tissues. In contrast, the expression of MMP-2 mRNA in
normal cells obtained from the margin of nodular BCCs
was stronger than in the normal cells located at an interface
of the infiltrative BCCs. This likely reflected silencing of
the mRNA expression in normal cells adjacent to infiltra-
tive BCCs. In turn, the overexpression of MMP-2 mRNA
Fig. 2 Mean (±SD)
expressions of mRNA for
matrix metalloproteinases 2
(MMP2) and 9 (MMP9) in the
tissues (T) of nodular (nBCC)
and infiltrative (iBCC) basal-
cell carcinoma and in normal
tissues adjacent to the tumors
(NT)
Table 1 Changes in mRNA
expression of MMP2, MMP9
and kol IV in nodular BCCs,
depending on gender
MMP2 T MMP2 NT MMP9 T MMP9 NT KOL IV T KOL IV NT
Women 0.83 ± 0.17 0.26 ± 0.08 0.32 ± 0.1 0.07 ± 0.03 13.58 ± 2.16 18.94 ± 2.86
Men 0.87 ± 0.1 0.31 ± 0.08 0.35 ± 0.2 0.07 ± 0.03 13.47 ± 3.24 20.24 ± 5.4
Table 2 Changes in mRNA
expression of MMP2, MMP9
and kol IV in infiltrative BCCs,
depending on gender
MMP2 T MMP2 NT MMP9 T MMP9 NT KOL IV T KOL IV NT
Women 1.03 ± 0.37 0.25 ± 0.11 0.53 ± 0.21 0.06 ± 0.01 15.06 ± 2.52 37.01 ± 7.45*
Men 0.89 ± 0.22 0.20 ± 0.06 0.54 ± 0.13 0.06 ± 0.01 13.91 ± 2 47.59 ± 12.9*
*Statistically significant differences
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in tissues surrounding nodular BCCs may a kind of coun-
terbalance effect: cancer cells from the collagen-entrapped
tumor may stimulate the synthesis of MMP-2 in normal
adjacent cells, e.g. acting via the EMMPRIM protein [34].
We showed that nodular BCCs were characterized by
significantly lower levels of MMP-9 mRNA than the
infiltrative tumors. This observation is consistent with the
results of many previous studies in which the invasiveness
of infiltrative BCCs was shown to be determined by their
elevated expression of MMP-9 [43–46].
Nodular BCCs were characterized by slightly lower
levels of type IV collagen mRNA than the infiltrative
BCCs [47, 48]. In turn, the expression of type IV collagen
mRNA in normal tissues from the interface of nodular
BCCs turned out to be significantly lower than in the
normal tissues surrounding infiltrative BCCs. Perhaps
normal cells adjacent to infiltrative BCCs show stronger
expression of mRNA for type IV collagen in order to
prevent their infiltration by cancer cells. Infiltrative BCCs
were shown to be more invasive than the nodular BCCs,
isolated from surrounding tissues by a capsule composed
of type I and III collagen [8].
ECM undergoes constant remodeling catalyzed by pro-
teolytic enzymes, among them metalloproteinases. A
number of previous studies showed an increase in the
expressions of MMP-2 and MMP-9 within various malig-
nancies, and these enzymes were proposed as potential
cancer markers [25, 44, 49–52]. Our findings are consistent
with the data published by Vempati et al. [46], Zlatarova
et al. [25], Fu et al. [50], El-Khalawany and Abou-Bakr
[24] and Vanjaka-Rogosic et al. [53], who showed that the
expression of MMP-9 may constitute a molecular marker
of processes taking place within the BCCs. However, the
evidence in this matter is inconclusive. For example,
Ciurea et al. [54] claimed that MMP-9 does not accurately
distinguish between the BCC and normal tissue.
Molecular markers of carcinogenesis
The proteolysis of ECM results from the activity of various
MMPs synthesized by a number of normal and neoplastic
cells [55]. The degradation of extracellular matrix is also
supported by many hormones, cytokines and growth fac-
tors that induce synthesis of proteolytic enzymes and their
inhibitors [39].
Varani et al. [45] showed that while most cancer tissues
express active forms of MMP-2 and MMP-9, the latent
forms of these enzymes can be predominantly found in the
normal tissues. According to Orimoto et al. [52], MMP-2 is
a very accurate marker distinguishing between BCCs and
surrounding normal tissues. In contrast, Chen et al. [49]
demonstrated the inhibition of MMP-2 expression in BCC
and put the diagnostic value of this marker into question.
These discrepancies substantiate further research on the
problem in question.
Conclusion
Cancer cells synthesize an array of factors that perpetuate
their proliferation and migration, and induce pathological
angiogenesis. At least some of these factors can be used as
markers of invasiveness, used to distinguish between
pathological and normal tissue at the molecular level. It is
of vital importance, as microscopic identification of the
tumor margin is often inaccurate, resulting in suboptimal
resection of BCC. Another potential application of novel
molecular markers is detection of carcinogenesis at early
preclinical stages [56]. Our hereby presented findings
suggest that MMP-2 and MMP-9 could be used as prog-
nostic factors of BCCs.
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metalloproteinases in gliomas. Postep Psychiatrii Neurol
17(3):207–211
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